ESC: Weight-Loss Drug Clears Major CV Hurdle - Medpage Today [rnaIrWBZz16]

| 1h 28m 28s | Video has closed captioning.

Erin Bohula, MD, DPhil MUNICH -- Longer-term use of the weight-loss drug lorcaserin (Belviq) revealed no excess major adverse cardiovascular event risk, results of the CAMELLIA-TIMI-61 postmarketing trial found. Medpage Today: Online CME - Continuing medical education: Latest medical news: The MedPage Today app: iOS: Android: MedPage Today Youtube Channel: Medpage Today on Facebook: #old diet pills #icon keto gummies #does go keto gummies work #sunny day acv keto

Aired: January 05, 2025

Rating: TV-14